262
A. S. Shinde et al.
Table 1
(continued)
Drug/active ingredients System components
Aim
Major applications
Route of
administration
Fullerenes
Diethyl bromomalonate C60
To neuroprotective
agent
Ex-cytotoxic necrosis,
protective effects of
neuronal apoptotic neuronal
deaths and increasing
intercalation into brain
membranes
In vitro
and
in vivo
Polymersome
Insulin
Dextran-b-poly(lactide-co-glycolide)
Oral delivery of
insulin
Insulin release in gastric
condition was negligible
and released in the
stimulated intestinal
condition. Permeability
increase compared with free
insulin
In vitro
and in
vivo
Hybrid
nanoparticles
Doxorubicin and
Mitomycin C
Polymer-lipid
Synergistic
activities
Increased biodistribution,
pharmacokinetics,
bioavailability and reduced
toxicity
Implantable
Niosomes
Doxorubicin
Sorbitan Monostearate
To improve
pharmacokinetics
and tumoricidal
activity
Increased bioavailability,
pharmacokinetics and
against multidrug resistance
In vivo
and
in vitro
Doxorubicin
C16 triglyceryl ether with or without
cholesterol
To distribution of
drugs
In vitro
drug release from
cholesterol-containing
niosomes is delayed,
in vivo,
there is little
difference between the two
preparations. More effective
reduction in tumor growth
In vitro
and
in vivo
(continued)